Shares of HilleVax, Inc. (NASDAQ:HLVX – Get Free Report) have been assigned an average recommendation of “Hold” from the six brokerages that are presently covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a hold recommendation. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $9.20.
HLVX has been the topic of a number of recent research reports. Leerink Partnrs lowered shares of HilleVax from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 9th. HC Wainwright reaffirmed a “neutral” rating and set a $2.00 target price (down from $28.00) on shares of HilleVax in a research note on Tuesday, July 9th. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $5.00 price target (down previously from $24.00) on shares of HilleVax in a research report on Monday, July 8th. SVB Leerink downgraded shares of HilleVax from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $28.00 to $2.00 in a research note on Tuesday, July 9th. Finally, Stifel Nicolaus cut HilleVax from a “buy” rating to a “hold” rating and reduced their price objective for the company from $34.00 to $3.00 in a research note on Tuesday, July 9th.
Read Our Latest Stock Analysis on HilleVax
HilleVax Stock Up 3.1 %
HilleVax (NASDAQ:HLVX – Get Free Report) last posted its earnings results on Thursday, May 9th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.13). Research analysts anticipate that HilleVax will post -2.58 EPS for the current year.
Insider Buying and Selling
In other HilleVax news, Director Aditya Kohli sold 6,000 shares of the stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $15.45, for a total value of $92,700.00. Following the sale, the director now directly owns 776,878 shares of the company’s stock, valued at approximately $12,002,765.10. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 71.10% of the stock is owned by insiders.
Institutional Investors Weigh In On HilleVax
Several institutional investors have recently modified their holdings of the company. EntryPoint Capital LLC acquired a new stake in HilleVax in the first quarter valued at $80,000. SG Americas Securities LLC acquired a new stake in shares of HilleVax during the 4th quarter worth about $139,000. Tidal Investments LLC purchased a new stake in HilleVax during the first quarter worth approximately $207,000. abrdn plc acquired a new position in HilleVax in the fourth quarter valued at approximately $433,000. Finally, Swiss National Bank boosted its holdings in HilleVax by 22.4% in the fourth quarter. Swiss National Bank now owns 38,200 shares of the company’s stock valued at $613,000 after purchasing an additional 7,000 shares in the last quarter. 86.42% of the stock is owned by hedge funds and other institutional investors.
About HilleVax
HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.
See Also
- Five stocks we like better than HilleVax
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Owens-Corning Stock: Good Value or Recession Red Flag?
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Datadog Exceeds Q2 Expectations, Solidifies Market Leadership
- What is the S&P/TSX Index?
- Cybersecurity Stock Surges, Promising Double-Digit Gains
Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.